Isomorphic Labs Just Raised $5 Billion. Here's What It Signals for AI Drug Discovery

ยท
Listen to this article~4 min

Isomorphic Labs closed a $5 billion Series C led by Greenoaks and Sequoia. Here's what the round signals for AI drug discovery and European startup funding in 2026.

Isomorphic Labs, the AI company focused on designing new medicines, just closed a $5 billion Series C round. Yes, you read that right. Five billion dollars. To put that in perspective, most European AI drug discovery startups are raising somewhere in the low millions right now. This single round dwarfs an entire year's worth of sector funding across the continent. ### Who's Behind the Money The round was co-led by Greenoaks and Sequoia Capital, with Andreessen Horowitz also stepping in. Alphabet kept its significant stake, and every existing investor returned: Thrive Capital, MGX, GV, CapitalG, Temasek, and the UK Sovereign AI Fund. When all your previous backers come back for more, that tells you something about conviction. Sir Demis Hassabis, founder and CEO, put it plainly: "Our drug design engine is generating molecules with unprecedented precision and speed." He says the money will fund foundational biology models, deeper disease understanding, and pushing their first therapeutic programs toward clinical trials. ### The Rest of Europe Is Playing a Different Game Here's the part worth sitting with. During 2026, other European AI drug discovery rounds have been respectable but modest: - Helical (London) raised $9.1 million for its virtual AI lab - Ternary Therapeutics secured $4.4 million for AI-designed molecular glues - Sable Bio attracted $3.4 million for drug safety - Orakl Oncology (France) raised $32.5 million - Rivercell brought in $23.8 million - Adaptyv Bio (Switzerland) announced $37.2 million for automated biological testing Add up all those rounds, plus a handful of others, and you land around $160.5 million for 2026. Excluding Isomorphic. That's the whole picture versus one company's single round. ### What IsoDDE Actually Does Founded in 2021, Isomorphic built what it calls IsoDDE, a drug design engine that unifies foundational simulation AI models across multiple therapeutic areas and drug modalities. In plain terms, it explores vast chemical spaces to design and refine molecules with the right drug-like properties. The precision claim matters. The company says its simulation models push predictions close to experimental accuracy. Combined with proprietary agents that reason over complex biological systems, those models feed directly into a multi-modality pipeline of therapeutic candidates. > "Every week we are making repeatable scientific advancements enabled by our models," says Max Jaderberg, President of Isomorphic Labs. "These translate directly into better molecular profiles with the potential to be new medicines." ### Why This Matters Beyond the Headline For anyone watching European startup incorporation and deep tech funding, the signal is clear. Capital is concentrating at the very top. A company with Alphabet's backing and Hassabis at the helm can pull $5 billion while brilliant smaller teams scrape together single-digit millions. That doesn't mean the smaller players are doomed. It means the bar for standing out has shifted. Founders in this space need proprietary technology, credible scientific leadership, and a story that convinces investors to bet big rather than spread thin. The gap between the haves and the have-nots in AI biotech is widening, and 2026 is making that impossible to ignore.